LamdaGen Corporation receives Official Notice from the USPTO of Allowance of Patent: DIGITAL LSPR FOR ENHANCED ASSAY SENSITIVITY

MENLO PARK, CA, January 18, 2021— LamdaGen Corporation, a privately-owned company focused on the development and commercialization of plasmonic biosensor systems for Point of Care (POC) diagnostics, announced today the United States Patent and Trademark Office has given Official Notice of Allowance to its patent application entitled DIGITAL LSPR FOR ENHANCED ASSAY SENSITIVITY which enables high sensitivity and quantitative POC diagnostic testing. This patent is part of a portfolio of patents and  patent applications that protect LamdaGen’s Plasmonic Amplification Technology (PAT) rapid immunoassay-based diagnostic technology.

 “We are pleased to strengthen our intellectual property protection with the addition of this patent in the US which further covers our core LAuRA diagnostic platform,” commented Randolph Storer, CEO and co-founder of LamdaGen Corporation. “We have consistently sought to protect and expand our plasmonics-based patent portfolio in the U.S. and worldwide.”

The Company’s digital PAT system is central to its LAuRA Diagnostic Platform. This rapid immuno-based POC system couples the high sensitivity and quantitation of lab-based ELISA tests with the simplicity and speed of lateral flow assays (LFA). The easy to use and economical system is ideal for greatly expanding access to high sensitivity and mobile diagnostic testing across multiple health sectors and geographies.

About LamdaGen Corporation

LamdaGen Corporation is a Silicon Valley developer of nano-based biosensors and powerful testing systems. The company’s mission is to develop and commercialize innovative technologies for disease detection wherever, and whenever, they are needed. We do this by focusing on providing high sensitivity global point of care diagnostics that are fast, simple, and available to improve human health and wellness. For additional information, please visit or email